DTIL
Precision BioSciences, Inc.
There isn't enough reported data to score DTIL yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
DTIL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
DTIL's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
DTIL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $7.23 | -10% |
| Current | 24x | $8.04 | — |
| Fair | 31x | $10.17 | +26% |
| Expensive | 35x | $11.52 | +43% |
Historical ranges are pointers, not guarantees.
DTIL's PE is 24x, but its earnings don't support one, so it isn't a reliable read right now.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over DTIL in the historical PE scenario, which offers more potential upside but is not a forecast.
DTIL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect DTIL's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
DTIL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.33 | +$9.59 |
| Q2 2026 | -$1.23 | +$8.44 |
| Q1 2026 | -$2.10 | +$0.77 |
| Q4 2025 | -$3.56 | -442% |
| Q3 2025 | -$9.26 | -5888% |
| Q2 2025 | -$9.67 | -3219% |
| Q1 2025 | -$2.87 | +$4.49 |
| Q4 2024 | $1.04 | +$17.00 |
DTIL has returned to profit: it earned $0.33 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over DTIL on earnings, with more consistent year-over-year improvement.
DTIL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $10.8M | +37272% |
| Q4 2025 | $34.2M | +5261% |
| Q3 2025 | $13K | -98% |
| Q2 2025 | $18K | -100% |
| Q1 2025 | $29K | -100% |
| Q4 2024 | $638K | -91% |
| Q3 2024 | $576K | -96% |
| Q2 2024 | $49.9M | +152% |
DTIL's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -84% | +76165 points |
| Q4 2025 | 37% | +3931 points |
| Q3 2025 | -158977% | -155283 points |
| Q2 2025 | -121539% | -121587 points |
| Q1 2025 | -76248% | -76225 points |
| Q4 2024 | -3894% | -3683 points |
| Q3 2024 | -3694% | -3599 points |
| Q2 2024 | 48% | +109 points |
DTIL's operating margin was −84% last quarter, up 76165 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over DTIL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
DTIL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.1M | +$138K |
| Q2 2026 | -$13.4M | +$6.8M |
| Q1 2026 | -$12M | +$7.2M |
| Q4 2025 | -$11.3M | +$7.5M |
| Q3 2025 | -$15.3M | -$9.3M |
| Q2 2025 | -$20.3M | -$5.4M |
| Q1 2025 | -$19.1M | -$49K |
| Q4 2024 | -$18.8M | -$10.4M |
DTIL has burned cash in almost every quarter: −$52M over the past year, against −$73M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over DTIL on cash generation, producing positive trailing cash flow while its opponent burns cash.
DTIL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.1% | +1.6M shares |
| 1 year | +148% | +16.4M shares |
| 3 years | +642% | +23.7M shares |
| 5 years | +1472% | +25.7M shares |
DTIL has 27M diluted shares, up 148% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over DTIL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
DTIL Net Leverage
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
DTIL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.8 | Neutral |
| Stochastic | 55.4 | Neutral |
DTIL's weekly RSI is 54 (neutral) and its Stochastic is 55 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
DTIL PE vs Healthcare Sector
| Metric | DTIL | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 26x | 5.8% below |
| PE % | 17 | 29 | 12 pts below |
DTIL has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
DTIL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.17 | 12% above |
| 20 week MA | $7.47 | 7.6% above |
| 50 week MA | $6.35 | 27% above |
| 100 week MA | $5.75 | 40% above |
| 200 week MA | $10.3 | 22% below |
DTIL has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 22% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over DTIL on trend strength, trading above more of its moving averages.
DTIL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $421.5 | $280.5 | -33% |
| 2021 | $280.5 | $254.1 | -9.4% |
| 2022 | $254.1 | $30.3 | -88% |
| 2023 | $30.3 | $11.0 | -64% |
| 2024 | $11.0 | $4.65 | -58% |
| 2025 | $4.65 | $4.23 | -9% |
| 2026 YTD | $4.23 | $8.04 | +90% |
DTIL has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.